AXCELLA HEALTH INC (AXLA) Stock Price, Quote, News and Overview
NASDAQ:AXLA - Nasdaq - US05454B2043 - Common Stock - Currency: USD
AXLA Quote, Performance and Key Statistics
4.58
-0.9 (-16.42%)
The current stock price of AXLA is 4.58 USD. In the past month the price decreased by -33.72%. In the past year, price decreased by -80.3%.
AXLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.7 | 321.60B | ||
| AMGN | AMGEN INC | 13.07 | 145.89B | ||
| GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
| ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
| BIIB | BIOGEN INC | 8.02 | 18.58B |
Related stock screener links
About AXLA
Company Profile
Axcella Health Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 11 full-time employees. The company went IPO on 2019-05-09. Axcella Health Inc. is a clinical-stage biotechnology company. The firm is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.
Company Info
AXCELLA HEALTH INC
840 Memorial Dr
Cambridge MASSACHUSETTS 02139 US
CEO: William R. Hinshaw
Employees: 11
Phone: 16178680949.0
AXCELLA HEALTH INC / AXLA FAQ
What is the stock price of AXCELLA HEALTH INC today?
The current stock price of AXLA is 4.58 USD. The price decreased by -16.42% in the last trading session.
What is the ticker symbol for AXCELLA HEALTH INC stock?
The exchange symbol of AXCELLA HEALTH INC is AXLA and it is listed on the Nasdaq exchange.
On which exchange is AXLA stock listed?
AXLA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AXCELLA HEALTH INC stock?
8 analysts have analysed AXLA and the average price target is 15870.1 USD. This implies a price increase of 346408.73% is expected in the next year compared to the current price of 4.58. Check the AXCELLA HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AXCELLA HEALTH INC worth?
AXCELLA HEALTH INC (AXLA) has a market capitalization of 13.51M USD. This makes AXLA a Nano Cap stock.
How many employees does AXCELLA HEALTH INC have?
AXCELLA HEALTH INC (AXLA) currently has 11 employees.
What are the support and resistance levels for AXCELLA HEALTH INC (AXLA) stock?
AXCELLA HEALTH INC (AXLA) has a support level at 4.46 and a resistance level at 11.25. Check the full technical report for a detailed analysis of AXLA support and resistance levels.
Should I buy AXCELLA HEALTH INC (AXLA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AXLA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AXLA, evaluating the profitability, health, valuation and growth aspects
- AXCELLA HEALTH INC (AXLA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AXCELLA HEALTH INC (AXLA) Sales and EPS estimates to see what analysts future expectations are.
- AXCELLA HEALTH INC (AXLA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AXCELLA HEALTH INC (AXLA) Insider and Institutional Ownership to learn about the owners and their transactions.
- AXCELLA HEALTH INC (AXLA) Stock Chart to make your own analysis
- AXCELLA HEALTH INC (AXLA) Latest news and press-releases to stay up to date.
Does AXCELLA HEALTH INC (AXLA) stock pay dividends?
AXLA does not pay a dividend.
When does AXCELLA HEALTH INC (AXLA) report earnings?
AXCELLA HEALTH INC (AXLA) will report earnings on 2024-03-28, after the market close.
What is the Price/Earnings (PE) ratio of AXCELLA HEALTH INC (AXLA)?
AXCELLA HEALTH INC (AXLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.25).
AXLA Technical Analysis
AXLA Financial Highlights
Over the last trailing twelve months AXLA reported a non-GAAP Earnings per Share(EPS) of -19.25. The EPS increased by 42.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -518.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AXLA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to AXLA. The Buy consensus is the average rating of analysts ratings from 8 analysts.